Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Laird, A. D.
Right arrow Articles by Mendel, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laird, A. D.
Right arrow Articles by Mendel, D. B.
Vol. 2, 461-469, May 2003     Molecular Cancer Therapeutics
© 2003 American Association for Cancer Research

Src Family Kinase Activity Is Required for Signal Tranducer and Activator of Transcription 3 and Focal Adhesion Kinase Phosphorylation and Vascular Endothelial Growth Factor Signaling in Vivo and for Anchorage-dependent and -independent Growth of Human Tumor Cells

A. Douglas Laird1, Guangmin Li, Katherine G. Moss, Robert A. Blake, Martin A. Broome, Julie M. Cherrington and Dirk B. Mendel

Preclinical Research and Exploratory Development [A. D. L., G. L., K. G. M., J. M. C., D. B. M.], Discovery Technology [R. A. B.], and Research [M. A. B.], SUGEN, Inc., South San Francisco, California 94080

1 To whom requests for reprints should be addressed, at SUGEN, Inc., 230 East Grand Avenue, South San Francisco, CA 94080. Phone: (650) 837-3674; Fax: (650) 837-3308; E-mail: Douglas-Laird{at}sugen.com

The Src family kinases (SFKs) Src and Yes are believed to play critical roles in tumor growth, angiogenesis, invasion, and dissemination. Using a panel of highly selective and structurally diverse Src inhibitors, we found that phosphorylation of signal transducer and activator of transcription 3 [STAT3 (Y705)] and focal adhesion kinase [FAK (Y861)] was SFK dependent in cultured human colon, breast, lung, and ovarian tumor cells. These findings were reproduced in vivo in target modulation studies using tumors derived from fibroblasts overexpressing activated Src. Additionally, treatment of mice with multiple Src inhibitors resulted in inhibition of phosphorylation of FAK (Y861) and of a putative Src autophosphorylation epitope (Y419) in HT-29 human colon tumor xenografts. Next we pharmacologically examined the requirement for SFKs in asynchronous proliferation of human tumor cells. At concentrations sufficient to selectively inhibit Src, structurally diverse Src inhibitors inhibited growth of cultured human colon, breast, and lung cells on plastic under low serum conditions. In addition, these compounds inhibited anchorage-independent growth of HT-29 human colon tumor cells in soft agar. The role of SFK activity in vascular endothelial growth factor signaling was also evaluated. Inhibition of SFK signaling using structurally distinct Src inhibitors resulted in complete inhibition of vascular endothelial growth factor-dependent vascular permeability in vivo. These data demonstrate that STAT3 (Y705) and FAK (Y861) phosphoepitopes are SFK-dependent in tumor cells and reveal a requirement for SFK function in tumor cell proliferation and vascular permeability.




This article has been cited by other articles:


Home page
Ann OncolHome page
G. Giaccone and P. A. Zucali
Src as a potential therapeutic target in non-small-cell lung cancer
Ann. Onc., July 1, 2008; 19(7): 1219 - 1223.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. Serrels, I. R.J. Macpherson, T.R. J. Evans, F. Y. Lee, E. A. Clark, O. J. Sansom, G. H. Ashton, M. C. Frame, and V. G. Brunton
Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib
Mol. Cancer Ther., December 1, 2006; 5(12): 3014 - 3022.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
O. Potapova, A. D. Laird, M. A. Nannini, A. Barone, G. Li, K. G. Moss, J. M. Cherrington, and D. B. Mendel
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248
Mol. Cancer Ther., May 1, 2006; 5(5): 1280 - 1289.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. J. Delfino, H. Stevenson, and T. E. Smithgall
A Growth-suppressive Function for the c-Fes Protein-Tyrosine Kinase in Colorectal Cancer
J. Biol. Chem., March 31, 2006; 281(13): 8829 - 8835.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
Q. Lin, R. Lai, L. R. Chirieac, C. Li, V. A. Thomazy, I. Grammatikakis, G. Z. Rassidakis, W. Zhang, Y. Fujio, K. Kunisada, et al.
Constitutive Activation of JAK3/STAT3 in Colon Carcinoma Tumors and Cell Lines: Inhibition of JAK3/STAT3 Signaling Induces Apoptosis and Cell Cycle Arrest of Colon Carcinoma Cells
Am. J. Pathol., October 1, 2005; 167(4): 969 - 980.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F. M. Johnson, B. Saigal, M. Talpaz, and N. J. Donato
Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non-Small Cell Lung Cancer Cells
Clin. Cancer Res., October 1, 2005; 11(19): 6924 - 6932.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
C. E. Ducker, J. J. Upson, K. J. French, and C. D. Smith
Two N-Myristoyltransferase Isozymes Play Unique Roles in Protein Myristoylation, Proliferation, and Apoptosis
Mol. Cancer Res., August 1, 2005; 3(8): 463 - 476.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. M. Golas, J. Lucas, C. Etienne, J. Golas, C. Discafani, L. Sridharan, E. Boghaert, K. Arndt, F. Ye, D. H. Boschelli, et al.
SKI-606, a Src/Abl Inhibitor with In vivo Activity in Colon Tumor Xenograft Models
Cancer Res., June 15, 2005; 65(12): 5358 - 5364.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. L. Silver, H. Naora, J. Liu, W. Cheng, and D. J. Montell
Activated Signal Transducer and Activator of Transcription (STAT) 3: Localization in Focal Adhesions and Function in Ovarian Cancer Cell Motility
Cancer Res., May 15, 2004; 64(10): 3550 - 3558.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.